MONCTON, NB, Sept. 14, 2018 CNW/ – Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of medical marijuana, is pleased to announce that the Company has signed a supply agreement with the Newfoundland and Labrador Liquor Corporation (NLC) in anticipation of the launch of a legal, adult use recreational cannabis market in the province.
We are pleased to have been accepted as a supplier to NLC. At Organigram, we are very proud of our Atlantic Canadian roots and the opportunities we have to offer our neighbours a broad choice of high-quality cannabis products.
Greg Engel, Organigram’s Chief Executive Officer
According to the terms of the agreement, Newfoundland and Labrador cannabis retailers will have access to almost 100% of Organigram’s entire product portfolio. Organigram will also play a role in the province’s e-commerce plans, allowing for consumers to order directly on-line.
As we approach legalization, we look forward to working with both the NLC and private retailers across the province to help ensure the right tools are in place to offer consumers in Newfoundland and Labrador an exceptional consumer experience.
Tim Emberg, Vice President of Sales and Commercial Operations, Organigram
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.
Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. In anticipation of the legal adult use recreational cannabis in Canada, Organigram has developed a portfolio of brands including The Edison Cannabis Company, Ankr Organics and Trailer Park Buds. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations (“ACMPR”).
